Pioglitazone HCl

For research use only. Not for use in humans.

目录号:S2046 别名: AD-4833, U-72107E 中文名称:盐酸吡格列酮

Pioglitazone HCl Chemical Structure

CAS No. 112529-15-4

Pioglitazone HCl (AD-4833, U-72107E) 是一种 cytochrome P450 (CYP)2C8CYP3A4 酶的抑制剂。Pioglitazone HCl 抑制CYP2C8、CYP3A4和CYP2C9的Ki值分别为1.7 μM、11.8 μM和32.1 μM。Pioglitazone HCl 也是一种选择性的 peroxisome proliferator-activated receptor-gamma (PPARγ) 激动剂,对人PPARγ和小鼠PPARγ的EC50值分别为0.93 μM和0.99 μM。Pioglitazone HCl 可抑制线粒体内铁的摄取、脂质过氧化和随后的铁死亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 647.01 现货
RMB 647.01 现货
RMB 1387.89 现货
RMB 3019.29 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Pioglitazone HCl发表文献5篇:

客户使用该产品的2个实验数据:

  • Primary hepatocytes were treated with or without 20μM Wy14643/Pioglitazone/Rosiglitazone for 24h followed by stimulation with or without 1μg/ml recombinant human FGF21 for 15min. FGF21 signaling was analyzed by phosphorylation of ERK1/2 and FRS2 examination.

    Mol Nutr Food Res, 2017, 61(9). Pioglitazone HCl purchased from Selleck.

    Accumulated 7-day BrdU labeling in representative sections of pancreatic islets from mice fed (A) normal chow, (B) HFD, (C) HFD+clodronate, and (D) HFD+pioglitazone. β-Cells were immunostained with anti-insulin Ab (green) and for replication with anti-BrdU Ab (red). Nuclei were stained in blue. Scale bar, 100 μm. The percentage of BrdU-positive β-cells was calculated. Values are means±SE with 5 pancreas samples in each experimental group analyzed and are shown in E. *P<0.05 where significant difference was detected between the HFD mice and other treatment groups. No significant difference was detected between the results of other groups.

    Endocrinology and Metabolism, 2016, 311(4): E763-E771.. Pioglitazone HCl purchased from Selleck.

产品安全说明书

P450 (e.g. CYP17)抑制剂选择性比较

生物活性

产品描述 Pioglitazone HCl (AD-4833, U-72107E) 是一种 cytochrome P450 (CYP)2C8CYP3A4 酶的抑制剂。Pioglitazone HCl 抑制CYP2C8、CYP3A4和CYP2C9的Ki值分别为1.7 μM、11.8 μM和32.1 μM。Pioglitazone HCl 也是一种选择性的 peroxisome proliferator-activated receptor-gamma (PPARγ) 激动剂,对人PPARγ和小鼠PPARγ的EC50值分别为0.93 μM和0.99 μM。Pioglitazone HCl 可抑制线粒体内铁的摄取、脂质过氧化和随后的铁死亡。
靶点
Ferroptosis [8]
()
hPPARγ [1]
(Cell-free assay)
rPPARγ [6]
(Cell-free assay)
CYP2C8 [7]
(Cell-free assay)
CYP3A4 [7]
(Cell-free assay)
0.93 μM(EC50) 0.99 μM(EC50) 1.7 μM(Ki) 11.8 μM(Ki)
体外研究

Pioglitazone抑制LPS诱导的iNOS表达和NO的产生,并抑制iNOS表达足以保护多巴胺神经元抗LPS损伤。Pioglitazone保护多巴胺能神经元免受LPS,至少通过抑制iNOS的表达和NO的产生,这是通过抑制p38蛋白激酶的活性介导的。Pioglitazone抑制p38蛋白的LPS诱导的磷酸化。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
COS cells NHnSbHdHfW6ldHnvckBie3OjeR?= M4\tXXRz[W6|Y4LpdJRqd26jbDDhZ5RqfmG2aX;uJIlvKEORUzDj[YxteyCneIDy[ZN{cW6pIGDQRXIh\2GvbXGgZY5lKFK[UjDhcJBp[TtidnHseYV{KGmwIITo[UBx[XKnboTo[ZNmeyCrbnTpZ4F1\XNiOUWlJINwdm[rZHXuZ4UhcW62ZYL2ZYwtKEWFNUC9NE41QSEQvF2= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTlyNkK5N{c,OTF7ME[yPVM9N2F-
HepG2 cells NYLYOpQ4TnWwY4Tpc44h[XO|YYm= NIfzRnhR\XKxeHnzc41mKHC{b3zp[oVz[XSxcjDhZ5RqfmG2ZXSgdoVk\XC2b4Kg[4FudWFiYXfvcol{fGmlIHHjeIl3cXS7IHnuJGhmeEd{IHPlcIx{NCCHQ{WwQVcvPiEQvF2= NYm4fnFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC3NVQ2ODNpPkGwO|E1PTB|PD;hQi=>
CV-1 NHftR5lHfW6ldHnvckBie3OjeR?= NU[2eFl1UW5idnn0do8hfHKjboPjdolxfGmxbnHsJIFkfGm4YYTpc44hd2ZiUHXyc5hqe2:vZTDwdo9tcW[ncnH0c5Ih[WO2aY\heIVlKHKnY3XweI9zKGejbX3hJEhRWEGUKTDlfJBz\XO|ZXSgbY4hS1ZvMTDj[YxteyxiRVO1NF0xNjZ7zszNMi=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek85PTd4OUC3K|45PTd4OUC3QE9iRg>?
3T3-L1 Ml[xSpVv[3Srb36gZZN{[Xl? M4fyfGVn\mWldHn2[UBkd26lZX70doF1cW:wIH\vdkA2OCViZX7oZY5k\W2nboSgc4YhcW6|dXzpck1qdmS3Y3XkJJRzcWeueXPldoll\SCjY3P1cZVt[XSrb36gbY4hO1R|LVyxJINmdGy|LDDFR|UxRTBwMUdOwG0v NH;S[JE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97NUm5NlQyLz57NUm5NlQyRC:jPh?=
CV-1 NVLFenRbTnWwY4Tpc44h[XO|YYm= MlPxRYN1cX[jdHnvckBw\iCyZYLvfIl{d22nIIDyc4xq\mW{YYTvdkBi[3SrdnH0[YQhemWlZYD0c5Ih\2GvbXGgcYVie3W{ZXSgZpkhcW6mdXP0bY9vKG:oIEWwKUBw\iCvYYjpcZVuKGGua3HsbY5mKHCqb4PwbIF1[XOnIHHjeIl3cXS7LDD0doFve2[nY4Tpc44h[XO|YYmgbY4hS1ZvMTDj[YxteyxiRVO1NF0xNjV6OEi0{txONg>? NIHXW5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEO2OlIxLz57OEO2OlIxRC:jPh?=
CV-1 MkjmSpVv[3Srb36gZZN{[Xl? Mnq0UYF5cW2jbDDy[ZBwenSncjDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTDHZYw1KGOqaX3ldolkKGmwIITyZY5{cWWwdHz5JJRz[W6|ZnXjeIVlKEOYLUGgZ4VtdHNiYomg[pVv[3Srb37hcEBie3OjeTygSWM2OD1yLkW4{txONg>? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTd{MEi1OEc,OTF5MkC4OVQ9N2F-
HEK293 M{T2[GZ2dmO2aX;uJIF{e2G7 MVjB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDy[YNmeHSxcjDpcpRmemGldHnvckB4cXSqIIP0[ZJwcWRicnXj[ZB1d3JiY3;hZ5RqfmG2b4KtNUBjgSCHWV\QJIJie2WmIILldI9zfGW{IHflcoUh[XO|YYm= M3\5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NkiwNVU6Lz5zNk[4NFE2QTxxYU6=
HEK293 MmT4SpVv[3Srb36gZZN{[Xl? NIr1NHFC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBz\WOncITvdkBqdnSncnHjeIlwdiC5aYToJJJmfGmwb3nkJHguemWlZYD0c5Ih[WyyaHGgZpkhTVmIUDDiZZNm\CC{ZYDvdpRmeiCpZX7lJIF{e2G7 MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
CV1 M1PHTWZ2dmO2aX;uJIF{e2G7 M{W3SnRz[W6|YXP0bZZifGmxbjDv[kBRWEGUZ3HtcYEhcW5iQ2[xJINmdGy|LDDFR|UxRTBwNUZOwG0v MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjh{MUe2PUc,OTZ6MkG3Olk9N2F-
Cos7 MWPGeY5kfGmxbjDhd5NigQ>? NXLnXll{OTRiaILz NGiwTo5VemGwc3HjeIl3[XSrb36gc4YhcHWvYX6gVHBCWmejbX3hJGxDTCCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS2:|NzDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIH\1d4VlKEeDTEStSGJFKGGodHXyJFE1KGi{czDifUBFfWGuLVfsc{BNfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5|zszNMi=> NWm3TnRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFc6QDFpPkKwN|A4QThzPD;hQi=>
3T3L1 MWXGeY5kfGmxbjDhd5NigQ>? NYOxbmVsOTByIIXtc4wwVA>? M2f1V2lv[3KnYYPlJIlvKFCSQWLnZY1u[SCvUl7BJIxmfmWuczDpckBud3W|ZTCzWFNNOSClZXzsd{BifCBzMECgeY1wdC:OIHL5JHJVNVCFUh?= NULUW3llRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPVI3PDVpPkKwN|kzPjR3PD;hQi=>
CHO NHXLfHVHfW6ldHnvckBie3OjeR?= Mnm0RYN1cX[jdHnvckBw\iCJYXy0MZRi\2enZDDoeY1idiCSUFHS[4FudWFiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MD6xOO69VS5? MmLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4NU[0PVQoRjJyNkW2OFk1RC:jPh?=
HEK293T M3v4ZWZ2dmO2aX;uJIF{e2G7 NXHLXI5nOSC3TR?= M3XjVVI1KGi{cx?= NH3zelVR[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hMWxDTCCneIDy[ZN{\WRiaX6gTGVMOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhemWlZYD0c5IhfHKjboPhZ5RqfmG2aX;uJIF1KDFidV2gZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> NYTrVII5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwN|AzPjNpPkKxNFMxOjZ|PD;hQi=>
COS-1 MlTUSpVv[3Srb36gZZN{[Xl? NYW2TG03SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBEV1NvMTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuN|nPxE1w M4DJXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUOwOlQ6Lz5{MUGzNFY1QTxxYU6=
CHO Mom1SpVv[3Srb36gZZN{[Xl? MUmyOEBpenN? MV;QZZJ1cWGuIHHnc45qe3RiYXP0bZZqfHliYYSgbJVu[W5iUGDBVodidW2jIHX4dJJme3OnZDDpckBEUE9iY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCJYXy0MZJme3CxboPpeoUhdHWlaX\ldoF{\SC{ZYDvdpRmeiCybHHzcYllKGGodHXyJFI1KGi{czDifUB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVA:OC5|Od88UU4> M1qwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{e3PFc2Lz5{MUO3O|g4PTxxYU6=
COS7 NW\lU3dpTnWwY4Tpc44h[XO|YYm= MUHNc4R2dGG2aX;uJI9nKGi3bXHuJHBRSVKpYX3tZU1NSkRiZYjwdoV{e2WmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEORU{egZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDHZYw1KGG|c3Xzd4VlKGG|IHHjeIl3[XSrb36gc4YhfHKjboPhZ5RqfmG2aX;uJIFkfGm4aYT5JIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9NE4{|ryPLh?= NF3sUng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi3N|A4OCd-MkG4O|MxPzB:L3G+
Sf21 NWPJUZVETnWwY4Tpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGJUTVBiZYjwdoV{e2WmIHnuJJBt[XOvYTDt[Y1jemGwZTD2[ZNq[2ynczDv[kBU\jJzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSVSSLXTldIVv\GWwdDDbN2hefGG3cn;jbI9t[XSnIIXweIFs\SxiSVO1NF0xNjQQvF2u MoDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkW2NlMoRjJzOU[1OlI{RC:jPh?=
Sf21 MoftSpVv[3Srb36gZZN{[Xl? NVnn[2VyUW6qaXLpeIlwdiCxZjDTdJJi\3WnLVThe4xmgSC{YYSgRpNmeCCneIDy[ZN{\WRiaX6gdIxie22jIH3lcYJz[W6nII\ld4lkdGW|IH;mJHNnOjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCXFBvZHXw[Y5l\W62IGuzTH11[XW{b3Poc4xifGVidYD0ZYtmNCCLQ{WwQVLPxE1w NEew[o89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OVYzOyd-MkG5OlU3OjN:L3G+
HepG2 Mn;0SpVv[3Srb36gZZN{[Xl? MmewNlAhcHK| M3LNPWFod26rc4SgZYN1cX[rdImgZZQhT0GOND30ZYdo\WRiaIXtZY4hWFCDUnfhcY1iKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbjDlfJBz\XO|ZXSgbY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgeJJidnOjY4TpeoF1cW:wIHHmeIVzKDJyIHjyd{BjgSCkZYThMYdidGGldH;zbYRie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkW3{txONg>? NHnQfmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO0NVU4Oyd-MkKzOFE2PzN:L3G+
HEK293 MlfnSpVv[3Srb36gZZN{[Xl? MXexPEBpenN? MWnUdoFve2GldHn2ZZRqd25ib3[gbJVu[W5iR1HMOE1nfXOnZDDQVGFT\2GvbXGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKHS{YX7z[oVkfGWmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyQCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE45|ryPLh?= M2mxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUCyPFkyLz5{M{GwNlg6OTxxYU6=
COS7 NXjrOox4TnWwY4Tpc44h[XO|YYm= NH\vWphVemGwc3HjeIl3[XSrb36gc4YhT0GOND3meZNm\CCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIITyZY5{\mWldHXkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMt88UU4> NFLBcJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GzNFk3PCd-MkOxN|A6PjR:L3G+
THP1 MlHtRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? MX6xJIhz MXrBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDQUWEucW6mdXPl[EBOS1BvMTDz[YNz\XSrb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJHBOSS2laHHscIVv\2VibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KEWOSWPBMEBKSzVyPUG4Mlg1|ryPLh?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhzMUC5Nkc,OjN6MUGwPVI9N2F-
THP1 NEXWe2RCdnSraX7mcIFudWG2b4L5JIF{e2G7 MYSyJIhzew>? MWDBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDQUWEucW6mdXPl[EBOS1BvMTDz[YNz\XSrb36gbY5kfWKjdHXkJIZweiB{IHjyd{BxemmxcjD0c{BRVUFiY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCHTFnTRUwhUUN3ME2xPE43|ryPLh?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV|MUKyO{c,OjR3M{GyNlc9N2F-
HEK293 NIraSYFHfW6ldHnvckBie3OjeR?= MWWxNEB2VQ>? NGHLUFYzPCCqcoO= M1LOVnRz[W6|YXP0bZZifGmxbjDv[kBRWEGULXfhcY1iKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{BifCBzMDD1UUBi\nSncjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 NGOzR5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi5NFA6OCd-MkS4PVAxQTB:L3G+
HEK293 MkDvSpVv[3Srb36gZZN{[Xl? MVOxPEBpenN? NX3GWIQxSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{BqdmO3YnH0[YQh\m:{IEG4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4zOc7:TT6= NUW1b3NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|M5PTNpPkK1N|M{QDV|PD;hQi=>
COS7 M{jyb2Z2dmO2aX;uJIF{e2G7 M4rQO3Rz[W6|YXP0bZZifGmxbjDv[kBpfW2jbjDQVGFT\2GvbXGg[ZhxemW|c3XkJIlvKEGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgbY5kfWKjdHXkJI93\XKwaXfoeEBjgSCmdXHsMYdtdyCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MD6y{txONg>? NEHLb3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5OVc1QSd-Mk[1PVU4PDl:L3G+
THP1 M2HheWZ2dmO2aX;uJIF{e2G7 MoD0NVAhfU1? NELuepMzPCCqcoO= M2X2ZnVxemWpdXzheIlwdiCxZjDBRmNCOSCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hXEiSMTDj[YxteyCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkheVCFUjDt[ZRpd2RicnXsZZRqfmVidH:gZ49vfHKxbB?= M2PDWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkKwNFY2Lz5{N{KyNFA3PTxxYU6=
THP1 MYPGeY5kfGmxbjDhd5NigQ>? M3;yTlExKHWP NWflOVlFOjRiaILz M2LW[HVxemWpdXzheIlwdiCxZjDBRmNIOSCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hXEiSMTDj[YxteyCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkheVCFUjDt[ZRpd2RicnXsZZRqfmVidH:gZ49vfHKxbB?= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ{MEC2OUc,Ojd{MkCwOlU9N2F-
COS7 MnXMSpVv[3Srb36gZZN{[Xl? NGjxOpg1OiCqcoO= MnzQWJJidnOjY4TpeoF1cW:wIH;mJGdCVDRvZoXz[YQhcHWvYX6gVHBCWmejbX3hJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gRYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VNzDj[YxteyCjZoTldkA1OiCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE42|ryPLh?= MnHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NkCyPFIoRjJ5NU[wNlgzRC:jPh?=
COS7 NEK3dmFHfW6ldHnvckBie3OjeR?= NUnXdmlLPDJiaILz NV;WcINRXHKjboPhZ5RqfmG2aX;uJIF1KEejbESg[pV{\WRiUGDBVodidW2jIFzCSEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJIFnfGW{IESyJIhzeyCkeTDseYNq\mW{YYPlJIF{e2G7LDDFR|UxRTBwM{NOwG0v MmOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NkmxPVUoRjJ5NU[5NVk2RC:jPh?=
COS7 Mlj1SpVv[3Srb36gZZN{[Xl? NIXmZYg1OiCqcoO= NGTRb4FVemGwc3HjeIl3[XSrb36gc4YhT2GuNDDmeZNm\CCqdX3hckBRWEGUZ3HtcYEhVEKGIHX4dJJme3OnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHHmeIVzKDR{IHjyd{BjgSCmdXHsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjN6zszNMi=> NXLCTmM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVg6QTRpPkK3PVE5QTl2PD;hQi=>
PC3 M2rTU2Z2dmO2aX;uJIF{e2G7 MXW1NEB2VQ>? NY\2UZVHOjRiaILz NXrIV2Z2UW6lcnXhd4UhcW5icEKxLHdCTjFrIIDyc5RmcW5iZYjwdoV{e2mxbjDpckBpfW2jbjDQR|Mh[2WubIOgZZQhPTBidV2gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUKyNEc,Ojh|OUWyNlA9N2F-
MDA-MB-231 NF74[G1HfW6ldHnvckBie3OjeR?= NInQdow2OCC3TR?= NGL3bHgzPCCqcoO= NEPNTpBKdmO{ZXHz[UBqdiCyMkGoW2FHOSlicILveIVqdiCneIDy[ZN{cW:wIHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgOVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M3zYclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{m1NlIxLz5{OEO5OVIzODxxYU6=
HEK293 M4K1VWZ2dmO2aX;uJIF{e2G7 MmPUNlQhcHK| MlPDWJJidnOjY4TpeoF1cW:wIHHjeIl3cXS7IHH0JGdidDRiZoXz[YQh\nWubDDs[Y5ofGhiaIXtZY4hWFCDUnfhcY1iKEyERDDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MT6x{txONg>? NVmwUJpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlUxQTlpPkK4OFY2ODl7PD;hQi=>
HEK293 NVzwdnA3TnWwY4Tpc44h[XO|YYm= NUPnTFFPPCCqcoO= NUPT[lFiXHKjboPy[ZBz\XO|aX;uJIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWG5H[WyyaHGgbY5lfWOnZDDOSk1s[XCyYVKgdJJwdW:2ZYKgZYN1cX[rdImgdJJmfHKnYYTl[EBnd3JiNDDodpMh\m:ubH;3[YQh[nliVF7GZYxxcGFic4TpcZVt[XSrb36gZYZ1\XJiMzDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUKy{txONg>? M1PkV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[1NFk6Lz5{OES2OVA6QTxxYU6=
SCC15 MoOxR5l1d3SxeHnjbZR6KGG|c3H5 M1LvVlUxKHWP NWHMbFM5OjRiaILz MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTR2MyPSClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJHBRSVKjbIDoZUB{cVKQQTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[XRiNUCgeW0h[W[2ZYKgNlQhcHK|IHL5JJJme2G8dYLpckBz\WS3Y4Tpc44h[XO|YYm= NEfzdW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUCzNVA3Oyd-MkmwN|ExPjN:L3G+
SCC15 NYfH[3R4S3m2b4TvfIlkcXS7IHHzd4F6 NFPYWWg2OCC3TR?= MUCyOEBpenN? Mn60R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2NEOTViY3XscJMhfHKjboPm[YN1\WRid3n0bEBRWEGUYnX0ZUB{cVKQQTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[XRiNUCgeW0h[W[2ZYKgNlQhcHK|IHL5JJJme2G8dYLpckBz\WS3Y4Tpc44h[XO|YYm= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB|MUC2N{c,OjlyM{GwOlM9N2F-
HepG2 MXLGeY5kfGmxbjDhd5NigQ>? MlnlNlQhcHK| M3Pz[2Fod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKGmwIHj1cYFvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiUGDSSUBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDkeYFtKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkK0{txONg>? NGLyW3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwNVg1Pid-M{CwNFE5PDZ:L3G+
HEK293BENA NYHteYUzTnWwY4Tpc44h[XO|YYm= MYSyOEBpenN? MWrUdoFve2GldHn2ZZRqd25ib3[gS2FNPC2odYPl[EBpfW2jbjDQVGFT\2GvbXGgeJJidnOoZXP0[YQhcW5iSFXLNlk{SkWQQTDj[YxteyCjZoTldkAzPCCqcoOgZpkhe3SnYXT5JIdtdy2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;Mj6wOVPPxE1w M4THSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{WxPVM{Lz5|MEO1NVk{OzxxYU6=
HEK293 NGfFfWJHfW6ldHnvckBie3OjeR?= M3nk[lE5KGi{cx?= MWLUdoFve2GldHn2ZZRqd25ib3[gbJVu[W5iZoXscEBt\W6pdHigVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZYZ1\XJiMUigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCkYYPl[EBtfW2rbnXzZ4Vv[2ViYYPzZZktKEWFNUC9NE4y|ryPLh?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4MkezPUc,OzB|NkK3N|k9N2F-
293H NVzrdJF6TnWwY4Tpc44h[XO|YYm= MV:xOkBpenN? MlK3WJJidnOjY4TpeoF1cW:wIH;mJGdCVDRvRFLEJIZ2e2WmIHj1cYFvKFCSQWLnZY1u[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6g[ZhxemW|c3XkJIlvKFWDUz3icIEhUEWOIEK5N2gh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxOkBpenNiZn;scI94\WRiYomgSnJGXCC|dXLzeJJifGViYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEKgbJJ{KGK7IGTSMWZTTVRiYYPzZZktKEWFNUC9NE4xQTkQvF2u NGThdHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVA6Pyd-M{C0NlkxQTd:L3G+
3T3L1 MVrGeY5kfGmxbjDhd5NigQ>? MV6xNEB2VQ>? MVKyOEBpenN? MlTZRYdwdmm|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5ibX;1d4UhO1R|TEGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hSVBzIH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkhW1mEUjDndoVmdiCmeXWgZoF{\WRiUmStVGNTKGGwYXz5d4l{ NGnXZZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5OFQ{Oid-M{C1PVQ1OzJ:L3G+
3T3L1 M4nW[2Z2dmO2aX;uJIF{e2G7 MUmxNEB2VQ>? Mm[1NlQhcHK| NHrVUoFC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDtc5V{\SB|VEPMNUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCFREO2JI1TVkFiZYjwdoV{e2mxbjDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nliU2nCVkBoemWnbjDkfYUh[mG|ZXSgVnQuWEOUIHHuZYx6e2m| MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV7NESzNkc,OzB3OUS0N|I9N2F-
3T3L1 NXrhOZVVTnWwY4Tpc44h[XO|YYm= NVLlUHpVOTBidV2= MmjjNlQhcHK| NUDmcGZ6SWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiaX6gcY92e2ViM2SzUFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iR3z1eFQhdVKQQTDlfJBz\XO|aX;uJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDTXWJTKGe{ZXXuJIR6\SCkYYPl[EBTXC2SQ2KgZY5idHm|aYO= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV7NESzNkc,OzB3OUS0N|I9N2F-
3T3L1 MYHGeY5kfGmxbjDhd5NigQ>? NYrwVI5JOTBidV2= NWHROIdrOjRiaILz NGPYWndC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDtc5V{\SB|VEPMNUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZHnwc45m[3SrbjDtVm5CKGW6cILld5Nqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFO\QmKg[5Jm\W5iZInlJIJie2WmIGLUMXBEWiCjbnHsfZNqew>? NGrpPGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5OFQ{Oid-M{C1PVQ1OzJ:L3G+
stem cells MkPtSpVv[3Srb36gZZN{[Xl? M4XNUVUh\GG7cx?= NEXBN|hKdmS3Y4Tpc44hd2ZiYXTpdI9o\W6nc3nzJIlvKGi3bXHuJIJwdmVibXHydo94NWSncnn2[YQhdWW|ZX7jbJlu[Wxic4TlcUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZHnwc45m[3SrbjDwdo9lfWO2aX;uJI1m[XO3cnXkJI9vKGSjeTC1JIlvKHC{ZYPlcoNmKG:oIFnEXEBjgSCHTFnTRUwhTUN3ME2wMlM2|ryPLh?= MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB4N{K2PVgoRjNyNkeyOlk5RC:jPh?=
HEK293T NHLKTGZHfW6ldHnvckBie3OjeR?= MVGxPEBpenN? M4m0cnRz[W6|YXP0bZZifGmxbjDv[kBnfWyuIHzlcod1cCCqdX3hckBRWEGUZ3HtcYEzKGW6cILld5Nm\CCrbjDISWszQTOWIHPlcIx{KGOxLXX4dJJme3OrbnegVHBTTSCjZoTldkAyQCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMkZOwG0v MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Nke0NUc,OzB4N{[3OFE9N2F-
HEK293T M2no[2Z2dmO2aX;uJIF{e2G7 NUH6fHZJOThiaILz NYq3V2JKXHKjboPhZ5RqfmG2aX;uJI9nKGOqaX3ldolkKEejbESgfYVie3RiRFLEJIZ2e2WmLWDQRXJo[W2vYTDMRmQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{Bkdy2neIDy[ZN{cW6pIGDQVmUh[W[2ZYKgNVghcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjN3zszNMi=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Nke0NUc,OzB4N{[3OFE9N2F-
HepG2 NF3l[mlHfW6ldHnvckBie3OjeR?= M13nTlMxKHWP MmXjRolv\GmwZzDh[oZqdmm2eTD0c{BPSUZzIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gcYl1d2Oqb37kdolidCC{ZYPwbZJifGmxbjDheEA{OCC3TR?= NH7Ydmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEe3NFE2PCd-M{C3O|AyPTR:L3G+
HepG2 NWKyWlk3TnWwY4Tpc44h[XO|YYm= MoK4N|AhfU1? MXPCbY5lcW6pIHHm[olvcXS7IITvJG5CTjFiaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKHKnc4DpdoF1cW:wIHH0JFMxKHWP NV\IWHl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C3O|AyPTRpPkOwO|cxOTV2PD;hQi=>
COS7 NV:3SXRwTnWwY4Tpc44h[XO|YYm= MYqzPUBpenN? MYDUdoFve2GldHn2ZZRqd25ib3[gS4FtPC2odYPl[EBpfW2jbjDQVGFT\2GvbXGgeJJidnOoZXP0[YQhcW5iQ1;TO{Bk\WyuczDjc{11emGwc3\lZ5Rm\CC5aYToJJBISUx3LWTLMZBIVDNiYX7kJJBT\W6waXzsZU1EVVZiaX7jeYJifGWmIH\vdkA{QSCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDFR|UxRTFwNN88UU4> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTZ2OEGyOUc,OzF4NEixNlU9N2F-
K562 NI[x[ldHfW6ldHnvckBie3OjeR?= NUHTbXJYOTBidV2= MnrWO|IhcHK| NX7qWng6UW6mdXP0bY9vKG:oIIPlcpNqfGm8YYTpc44hfG9iaX3heIlvcWJvaX7keYNm\CCleYTveI95cWOrdImgbY4hcW2jdHnubYIuemW|aYP0ZY51KGi3bXHuJGs2PjJvSV3BX5JeKGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIF1KDFyIIXNJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kAyKHWPIHntZZRqdmmkIHL5JJBzd3CrZHn1cUBqd2SrZHWvWJJqfG:wLWixNFAh\HmnIHLhd4VlKE[DQ2OgZY5idHm|aYO= NUS4emY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G2OFgyOjVpPkOxOlQ5OTJ3PD;hQi=>

... Click to View More Cell Line Experimental Data

体内研究

在雄性肥胖鼠中,Pioglitazone口服(0.3-3毫克/公斤/天7天)剂量依赖性地降低了高血糖症,高脂血症,和高胰岛素血症。在大鼠中,Pioglitazone改善葡萄糖耐受性和增加外源性胰岛素和血浆甘油三酯的清除。[2] 在未处理的SOD1-G93A小鼠中,Pioglitazone处理转基因小鼠显示改进的肌肉力量和体重,表现出延迟疾病发作和显著较长生存比。[3] 在大鼠和小鼠中,Pioglitazone显著降低高血糖症,高脂血症,高胰岛素血症,葡萄糖不耐症,其特征如胰岛素抵抗状态。在黄色的KK小鼠的隔膜和脂肪组织中,Pioglitazone在的胰岛素介导的葡萄糖代谢。在Zucker肥胖大鼠中,Pioglitazone增强在源性胰岛素的血糖反应。[4] 在APPV717I转基因小鼠的海马和皮层活性星形细胞中,Pioglitazone导致激活的小胶质细胞的数量减少。在APPV717I转基因小鼠中,Pioglitazone降低β-分泌-1(BACE1)的mRNA和蛋白水平。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 79 mg/mL (201.06 mM)
Ethanol 4 mg/mL (10.18 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 392.9
化学式

C19H20N2O3S.HCl

CAS号 112529-15-4
储存条件 粉状
溶于溶剂
别名 AD-4833, U-72107E

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04501406 Recruiting Drug: Pioglitazone|Other: Placebo Type 2 Diabetes Mellitus (T2DM)|Nonalcoholic Steatohepatitis University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) December 15 2020 Phase 2
NCT04535700 Recruiting Drug: Pioglitazone 30 mg|Other: standard of care Type 2 Diabetes Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal September 18 2020 Phase 4
NCT00904046 Recruiting Drug: Pioglitazone|Drug: Placebo Uric Acid Kidney Stone Disease University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America Inc. September 5 2019 Not Applicable
NCT04671056 Completed Drug: MGL-3196|Drug: Pioglitazone 15mg Healthy Madrigal Pharmaceuticals Inc. November 9 2018 Phase 1
NCT03501277 Completed Drug: Alogliptin|Drug: Pioglitazone|Drug: SYR-322-4833 BL Healthy Volunteers Takeda May 26 2018 Phase 1
NCT03471117 Recruiting Drug: Pioglitazone|Other: Placebo Chronic Kidney Diseases The University of Texas at Arlington|University of Texas Southwestern Medical Center at Dallas April 1 2018 Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

P450 (e.g. CYP17) Signaling Pathway Map

相关P450 (e.g. CYP17)产品

Tags: 购买Pioglitazone HCl | Pioglitazone HCl供应商 | 采购Pioglitazone HCl | Pioglitazone HCl价格 | Pioglitazone HCl生产 | 订购Pioglitazone HCl | Pioglitazone HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID